{
  "metadata": {
    "case_id": 35,
    "model": "Claude-4.5-Sonnet",
    "timestamp": "2025-11-29T15:54:52.341169",
    "total_alignments": 2,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/35_NCT03019588.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/Claude-4.5-Sonnet/35_Claude-4.5-Sonnet.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.98,
          0.3
        ],
        [
          0.4,
          0.98
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "label": "Pembrolizumab 200 mg",
            "type": "EXPERIMENTAL",
            "description": "Participants receive pembrolizumab 200 mg intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).",
            "interventionNames": [
              "Biological: Pembrolizumab"
            ]
          },
          "pred_item": {
            "label": "Pembrolizumab",
            "type": "EXPERIMENTAL",
            "description": "Patients received 200 mg of pembrolizumab intravenously every 3 weeks for up to 35 cycles (approximately 2 years) or until disease progression, intolerable toxicity, investigator decision, or patient withdrawal of consent.",
            "interventionNames": [
              "DRUG: Pembrolizumab"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "label": "Paclitaxel 80 mg/m^2",
            "type": "ACTIVE_COMPARATOR",
            "description": "Participants receive paclitaxel 80 mg/m\\^2 IV infusion on Days 1, 8 and 15 of each 4-week cycle for up to approximately 2 years.",
            "interventionNames": [
              "Drug: Paclitaxel"
            ]
          },
          "pred_item": {
            "label": "Paclitaxel",
            "type": "ACTIVE_COMPARATOR",
            "description": "Patients received 80 mg/m² of paclitaxel intravenously on days 1, 8, and 15 of each 4-week cycle until disease progression, intolerable toxicity, investigator decision, or patient withdrawal of consent.",
            "interventionNames": [
              "DRUG: Paclitaxel"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.96,
          0.2
        ],
        [
          0.18,
          0.95
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "type": "BIOLOGICAL",
            "name": "Pembrolizumab",
            "description": "IV infusion",
            "armGroupLabels": [
              "Pembrolizumab 200 mg"
            ],
            "otherNames": [
              "MK-3475"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Pembrolizumab",
            "description": "200 mg administered intravenously every 3 weeks for up to 35 cycles (approximately 2 years)",
            "armGroupLabels": [
              "Pembrolizumab"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.95,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Paclitaxel",
            "description": "IV infusion",
            "armGroupLabels": [
              "Paclitaxel 80 mg/m^2"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Paclitaxel",
            "description": "80 mg/m² administered intravenously on days 1, 8, and 15 of each 4-week cycle",
            "armGroupLabels": [
              "Paclitaxel"
            ]
          }
        }
      ]
    }
  ]
}